MDM2 (12q15) Amplification, Well-Differentiated Liposarcoma/Atypical Lipomatous Tumor, FISH, Tissue
Use
This test is useful for identifying MDM2 amplification, which supports the diagnosis of several neoplasms such as well-differentiated liposarcoma, atypical lipomatous tumor, dedifferentiated liposarcoma, parosteal osteosarcoma, and central low-grade osteosarcoma. MDM2 amplification by fluorescence in situ hybridization may provide valuable diagnostic support in the appropriate clinical and histopathologic contexts.
Special Instructions
It is important to submit a formalin-fixed, paraffin-embedded tumor tissue block for optimal results. For pathology consultation, order PATHC / Pathology Consultation, and an appropriate FISH test will be added at an additional charge. Ensure all submissions include a detailed pathology report and reason for testing, as absence of these may delay processing.
Limitations
The test is not FDA approved and serves as an adjunct to existing clinical and pathologic information. Different fixatives like Prefer or Bouin's may affect FISH test outcomes. Decalcified specimens have about a 50% success rate in FISH testing. Other chromosome abnormalities won't be ruled out by this test.
New York Approved
Methodology
Chromosomal / Cytogenetics (FISH)
Biomarkers
LOINC Codes
- 93808-4
- 50397-9
- 69965-2
- 62356-1
- 31208-2
- 80398-1
- 19139-5
- 42349-1
- 85069-3
- 48767-8
- 62364-5
Result Turnaround Time
7-10 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Collection Instructions
Submit a formalin-fixed, paraffin-embedded tumor tissue block. Alternatively, submit 1 slide stained with hematoxylin and eosin and 4 consecutive unstained, positively charged, unbaked slides with 5 micron-thick sections of the tumor tissue.